Turnstone Biologics Corp.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TSBX research report →
Range $0.5 – $0.5
Price Chart
About the company
Turnstone Biologics Corp. is a clinical-stage biotechnology firm dedicated to developing therapeutic and curative treatments for patients battling solid tumor cancers. Its leading investigational drug, TIDAL-01, is currently undergoing Phase 1 clinical trials for indications such as breast cancer, colorectal cancer, and uveal melanoma.
- CEO
- Sammy J. Farah
- IPO
- 2023
- Employees
- 14
- HQ
- LA Jolla, CA, US
Get TickerSpark's AI analysis on TSBX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $8.21M
- P/E
- -0.47
- PEG
- -0.01
- P/S
- 0.00
- P/B
- 0.56
- EV/EBITDA
- 0.47
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -99.55%
- ROIC
- -91.09%
Latest fiscal year · YoY change
- Revenue
- $0-100.0%
- Gross Profit
- $-1,835,000-111.1%
- Op Income
- $-72,494,000
- Net Income
- $-70,837,000-28.3%
- EPS
- $-3.07-12.5%
- OCF Growth
- -1.9%
- FCF Growth
- -0.4%
- 52W High
- $2.26
- 52W Low
- $0.29
- 50D MA
- $0.36
- 200D MA
- $0.41
- Beta
- 1.37
- RSI (14)
- 49
- Avg Volume
- 404.93K
No earnings-call transcripts are available for TSBX yet.
- Free Float
- 74.5%
- Shares Outstanding
- 23.14M
- Float Shares
- 17.23M
of shares held by institutions
23 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock Inc. | 41.34K | ▼ 622.06K |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 8, 25 | ORBIMED ADVISORS LLC | other | 3,099,265 |
| Aug 8, 25 | Versant Ventures V, LLC | other | 274,990 |
| Aug 8, 25 | Jerel Davis | other | 82,006 |
| Aug 8, 25 | Gupta Rishi | other | 3,099,265 |
| Jun 3, 24 | Rajangam Kanya | other | 12,770 |
| Jun 3, 24 | Gould Robert J | other | 12,770 |
| Jun 3, 24 | Gupta Rishi | other | 12,770 |
| Jun 3, 24 | Jerel Davis | other | 12,770 |
| Jun 3, 24 | Waddill William D. | other | 12,770 |
| Apr 15, 24 | Waddill William D. | other | 25,540 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our TSBX coverage
Recent articles, reports, and earnings notes.
No research on TSBX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate TSBX report →$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Turnstone Biologics Corp. (NASDAQ: TSBX)
globenewswire.com · Jun 30
TSBX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Turnstone Biologics Corp. Is Fair to Shareholders
businesswire.com · Jun 27
Turnstone Biologics Corp. Reports First Quarter 2025 Financial Results and Provides Recent Corporate Highlights
globenewswire.com · May 8
Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2024 Financial Results
globenewswire.com · Mar 28
Turnstone Biologics Corp. (TSBX) Upgraded to Buy: What Does It Mean for the Stock?
zacks.com · Feb 7
Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
globenewswire.com · Nov 5
Turnstone Biologics Shifts Focus To 'High Unmet Medical Need' Cancers, Shares Initial Data From Colorectal Cancer Cell Therapy Study
benzinga.com · Aug 15
Why Is Turnstone Biologics (TSBX) Stock Down 38% Today?
investorplace.com · Aug 15
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.